ID

45925

Description

Principal Investigator: Francine Garrett-Bakelman, MD, PhD, University of Virginia, Charlottesville, VA, USA; Weill Cornell Medical College, New York, NY, USA MeSH: Acute Myeloid Leukemia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001027 Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and many others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through assessing genomics signatures in patient specimens collected through an international collaboration which assembled samples from 138 AML patients which experienced disease relapse and normal hematopoietic cells (n=15). It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.

Lien

dbGaP study = phs001027

Mots-clés

Versions (1)
  1. 27/02/2024 27/02/2024 - Simon Heim
Détendeur de droits

Francine Garrett-Bakelman, MD, PhD, University of Virginia, Charlottesville, VA, USA; Weill Cornell Medical College, New York, NY, USA

Téléchargé le

27 février 2024

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

dbGaP phs001027 Epigenomics Studies in Acute Myeloid Leukemia (AML)

Anglais

Eligibility Criteria

6 Formulaires  
Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Inclusion and exclusion criteria for specimens included:
Description

Inclusion and exclusion criteria for specimens included:

Type de données

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
UMLS CUI [1,3]
C0370003
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
Description

Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.

Type de données

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C2735298
UMLS CUI [1,3]
C5206782
UMLS CUI [1,4]
C4272796
UMLS CUI [1,5]
C1521750
UMLS CUI [1,6]
C0282564
UMLS CUI [1,7]
C0604937
UMLS CUI [1,8]
C0587348
UMLS CUI [1,9]
C0470187
UMLS CUI [1,10]
C2707520
UMLS CUI [1,11]
C1442880
UMLS CUI [1,12]
C0011900
UMLS CUI [1,13]
C0035020
UMLS CUI [2,1]
C3845275
UMLS CUI [2,2]
C0150103
UMLS CUI [2,3]
C5192904
UMLS CUI [2,4]
C0001779
UMLS CUI [2,5]
C0686906
UMLS CUI [2,6]
C0018939
UMLS CUI [2,7]
C5205410
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
Description

Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0023487
UMLS CUI [1,3]
C0087111
UMLS CUI [1,4]
C0282564
UMLS CUI [1,5]
C0604937
UMLS CUI [1,6]
C0857127
UMLS CUI [2,1]
C0205336
UMLS CUI [2,2]
C3843629
UMLS CUI [2,3]
C0332137
Retour au début de la page

Similar models

Eligibility Criteria

6 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Inclusion and exclusion criteria for specimens included:
Item
Inclusion and exclusion criteria for specimens included:
boolean
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
Item
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
boolean
C1512693 (UMLS CUI [1,1])
C2735298 (UMLS CUI [1,2])
C5206782 (UMLS CUI [1,3])
C4272796 (UMLS CUI [1,4])
C1521750 (UMLS CUI [1,5])
C0282564 (UMLS CUI [1,6])
C0604937 (UMLS CUI [1,7])
C0587348 (UMLS CUI [1,8])
C0470187 (UMLS CUI [1,9])
C2707520 (UMLS CUI [1,10])
C1442880 (UMLS CUI [1,11])
C0011900 (UMLS CUI [1,12])
C0035020 (UMLS CUI [1,13])
C3845275 (UMLS CUI [2,1])
C0150103 (UMLS CUI [2,2])
C5192904 (UMLS CUI [2,3])
C0001779 (UMLS CUI [2,4])
C0686906 (UMLS CUI [2,5])
C0018939 (UMLS CUI [2,6])
C5205410 (UMLS CUI [2,7])
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
Item
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
boolean
C0680251 (UMLS CUI [1,1])
C0023487 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0282564 (UMLS CUI [1,4])
C0604937 (UMLS CUI [1,5])
C0857127 (UMLS CUI [1,6])
C0205336 (UMLS CUI [2,1])
C3843629 (UMLS CUI [2,2])
C0332137 (UMLS CUI [2,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial